Curcumin Regulates Colon Cancer by Inhibiting P-Glycoprotein in In-situ Cancerous Colon Perfusion Rat Model

Area of Science:

• Pharmacology
• Cancer Biology
• Drug Delivery

Background:

• P-glycoprotein (P-gp) efflux pumps limit chemotherapy efficacy in colon cancer.
• In vitro studies on P-gp inhibitors often fail to translate to in vivo results.
• Curcumin shows potential as an adjuvant therapy by modulating P-gp.

Purpose of the Study:

• To investigate the in vivo efficacy of curcumin as a P-glycoprotein inhibitor in colon cancer.
• To evaluate the impact of curcumin on irinotecan permeability in a rat model of colon cancer.

Main Methods:

• Colon cancer was induced in rats using N-Nitroso N-methyl urea.
• In situ colon perfusion with irinotecan was performed in control, cancerous, and treated groups (verapamil, curcumin).
• P-glycoprotein expression and irinotecan permeability were quantified using qRT-PCR, Western blot, and HPLC-UV.

Main Results:

• Curcumin treatment led to a 15-fold decrease in P-glycoprotein expression.
• Curcumin pre-treatment increased irinotecan permeability by approximately 7-fold in cancerous colons.
• Both verapamil and curcumin significantly enhanced irinotecan's permeability in the colon.

Conclusions:

• Curcumin demonstrates significant in vivo P-glycoprotein inhibitory activity in colon cancer.
• Curcumin holds promise as an adjuvant therapy to improve irinotecan's therapeutic benefit.
• Developing safe P-glycoprotein inhibitors alongside irinotecan can enhance colon cancer treatment outcomes.